HYBIO plans to raise no more than 968 million yuan through a private placement for multiple projects and to supplement working capital
HYBIO plans to issue A-shares to no more than 35 specific investors, raising no more than 968 million yuan. The issuance price will be 80% of the average price of the 20 trading days prior to the pricing benchmark date. The raised funds will be used for the expansion and construction of peptide drug production lines, green intelligent upgrades, research laboratory upgrades, and to supplement working capital
According to the Zhitong Finance APP, Hanyu Pharmaceutical (300199.SZ) has disclosed a plan to issue A-shares to specific investors for the year 2025. The company intends to issue shares to no more than 35 specific investors (including 35). The issuance price will not be less than 80% of the average trading price of the company's shares over the 20 trading days prior to the pricing benchmark date. The number of shares will be determined by dividing the total amount of funds raised by the issuance price, and will not exceed 30% (including this number) of the company's total share capital before this issuance to specific investors.
The total amount of funds raised in this issuance will not exceed 968 million yuan (including this amount), and the net amount of funds raised after deducting relevant issuance expenses will be used entirely for the peptide drug production line and green intelligent expansion project, peptide fragment expansion construction project, research laboratory upgrade project, semaglutide research and development project, and to supplement working capital
